Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.
Korver SK, Bowen JM, Gibson RJ, Ball IA, Secombe KR, Wain TJ, Logan RM, Tuke J, Mead KR, Richards AM, Karapetis CS, Keefe DM, Coller JK. Korver SK, et al. Among authors: karapetis cs. Cancer Chemother Pharmacol. 2023 Jun;91(6):507-521. doi: 10.1007/s00280-023-04538-3. Epub 2023 May 10. Cancer Chemother Pharmacol. 2023. PMID: 37162533 Free PMC article.
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.
Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ; Adelaide Cancer Trials and Education Collaborative (ACTEC). Pittman KB, et al. Among authors: karapetis cs. Br J Cancer. 2006 Nov 20;95(10):1309-13. doi: 10.1038/sj.bjc.6603440. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088914 Free PMC article. Clinical Trial.
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Bowen JM, White I, Smith L, Tsykin A, Kristaly K, Thompson SK, Karapetis CS, Tan H, Game PA, Irvine T, Hussey DJ, Watson DI, Keefe DM. Bowen JM, et al. Among authors: karapetis cs. Support Care Cancer. 2015 Nov;23(11):3165-72. doi: 10.1007/s00520-015-2696-7. Epub 2015 Mar 27. Support Care Cancer. 2015. PMID: 25814442
Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.
Roder D, Karapetis CS, Olver I, Keefe D, Padbury R, Moore J, Joshi R, Wattchow D, Worthley DL, Miller CL, Holden C, Buckley E, Powell K, Buranyi-Trevarton D, Fusco K, Price T. Roder D, et al. Among authors: karapetis cs. BMJ Open. 2019 Sep 30;9(9):e031421. doi: 10.1136/bmjopen-2019-031421. BMJ Open. 2019. PMID: 31575579 Free PMC article.
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
White C, Wardill H, Paul C, Price T, Karapetis C, Nalder M, Burge ME, Thomas A, Oldmeadow C, Barker D, Edney LC, Coller J, Bowen J, Ostroff C, Cheek B, Carlson M, Rankmore T, Nagrial A, Clarke S, Chantrill L, Ackland S, Scott RJ. White C, et al. BMC Cancer. 2024 Nov 8;24(1):1369. doi: 10.1186/s12885-024-13122-8. BMC Cancer. 2024. PMID: 39516829 Free PMC article.
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group. Ferraro D, et al. Among authors: karapetis cs. Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335026 Clinical Trial.
179 results